-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VERBAleC0GH31smFIj570a6eLSRobUbINWjmJWjj9godNIBzQRiW59MJS9x0b1rc
 HYoA7FFsJTYUxCl4ii8L2w==

<SEC-DOCUMENT>0001178913-10-003427.txt : 20101230
<SEC-HEADER>0001178913-10-003427.hdr.sgml : 20101230
<ACCEPTANCE-DATETIME>20101230070121
ACCESSION NUMBER:		0001178913-10-003427
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101230
FILED AS OF DATE:		20101230
DATE AS OF CHANGE:		20101230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		101279417

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1009245.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1009245.htm</title>
    <!-- Licensed to: 01edgar09 -->
    <!-- Document Created using EDGARizer 5.3.0.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">for the month of December 2010</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Compugen Ltd.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant's name in English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">72 Pinchas Rosen Street, Tel-Aviv 69512, Israel</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F&#160;<font style="DISPLAY: inline;" face="Wingdings">x<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font>&#160;Form 40-F <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 30, 2010, Compugen Ltd. (the "Registrant") issued a Press Release, filed as Exhibit 1 to this Report on Form 6-K, which is hereby incorporated by reference herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="55%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="45%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compugen Ltd.</font> </font>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160; &#160;<font style="TEXT-DECORATION: underline">Ms. Dikla Czaczkes Axselbrad</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;Chief Financial Officer</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: December 30, 2010</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>EXHIBIT 1
<TEXT>
<html>
<head>
    <title>exhibit_1.htm</title>
    <!-- Licensed to: 01edgar09 -->
    <!-- Document Created using EDGARizer 5.3.0.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="compugen_bw.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For Release</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Compugen Signs $5 Million R&amp;D Funding Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">in Support of its Pipeline Program</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Baize Investments to obtain a financial interest in five program molecules</font> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">and a </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">30-month warrant to purchase 500,000 Compugen shares at $6.00 per share</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel Aviv, Israel, December 30, 2010 --- Compugen Ltd. <font style="DISPLAY: inline; TEXT-DECORATION: underline">(NASDAQ: CGEN)</font> announced today that it has entered into an agreement with Baize Investments (Israel) Ltd., a private corporation investing, inter alia, in innovative medical technologies, under which it will receive $5,000,000 in R&amp;D funding. Under the terms of the funding agreement, which is in support of Compugen's recently announced Pipeline Program, Baize Investments has obtained a financial interest in five designated Compugen-discovered molecules and has been issued a warrant to purchase 500,000 Compugen shares at an exercise price of $6.00 per share, expiring June 30, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Baize Investments' financial interest in the five designated molecules consists of the right to receive from Compugen up to 10% of certain future payments received by Compugen from third parties in the event of the successful licensing out for development and/or commercialization of such designated Compugen molecules. Currently, all five molecules are in active research in the Company's Pipeline Program, with their current status ranging from <font style="FONT-STYLE: italic; DISPLAY: inline">in silico</font> selection to post animal model validation. In addition, the investor has the right, until June 30, 2013, to waive his right to receive all such future payments in exchange for 833,334 Compugen ordinary shares.&#160;&#160;The financial terms for the investor were established based on the assumption that any out-licensing of the designa
ted molecules would be undertaken no later than IND filing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Martin Gerstel, Compugen's Chairman, stated, "This arrangement is an excellent example of how we can financially leverage our unique predictive product candidate discovery infrastructure to provide an increasing number of novel and attractive product candidates for potential licensing. Given the continuous expansion and improvement of this infrastructure, the <font style="FONT-STYLE: italic; DISPLAY: inline">in silico</font> prediction and selection of candidates is from a practical standpoint, essentially without limit as to the number of attractive candidates that can feed our Pipeline Program, and on an extremely cost-effective and systematic basis. Recently we announced the addition of twenty such novel molecules to the Program, and more have been added since that announcement. The funds received by Compugen pursuant to the agreement 
being announced today will allow us to pursue more aggressively our ambitious objectives for the Pipeline Program during the next few years."</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Gerstel continued, "In view of their long-term interest in the activities of the Company, we are very pleased to have Baize Investments and Mr. Murray Goldman join the Compugen team in this very meaningful endeavor."</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Murray Goldman, Baize Investments' Chairman, stated, "During the past few years, we have followed Compugen's scientific progress and growing predictive discovery capabilities. We are extremely pleased to become a financial partner in advancing these exciting product candidates, all of which have the potential to address significant unmet medical needs."</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">About Compugen</font>'<font style="DISPLAY: inline; FONT-WEIGHT: bold">s Pipeline Program</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen utilizes its systematic and broadly applicable predictive discovery capabilities to provide product candidates to the drug and diagnostic industries under licensing and other commercialization arrangements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2010, the company's Pipeline Program was initiated to both expand the number of <font style="FONT-STYLE: italic; DISPLAY: inline">in silico</font> predicted and selected therapeutic candidates undergoing <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font> and <font style="FONT-STYLE: italic; DISPLAY: inline">in vivo</font> validation, and to significantly enhance the commercial value of Compugen's product candidate pipeline by advancing certain candidates 12-18 months beyond the successful animal disease model proof of concept stage. In October 2010, Compugen announced that approximately 20 novel molecules had entered the Pipeline Program, in addition to eight molecules that had at that time already successfully completed animal disease model or similar therapeutic proof of concept validation studies, and additional m
olecules have been added since then to the Pipeline Program. The current areas of focus for the Pipeline Program are oncology and immunology therapeutics, primarily in the form of protein, peptide and monoclonal antibody drug candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">About Compugen</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on <font style="FONT-STYLE: italic; DISPLAY: inline">in silico</font> (by computer) product candidate prediction and selection utilizing a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools to address important unmet therapeutic and diagnostic needs &#8211; both for Compugen and its partners. Compugen's growing number of collaborations covering the further development and commercialization of Compugen-discovered product candidates provides Compugen with potential milestone payments and royalties on product sa
les or other forms of revenue sharing. These collaborations may be entered into before product candidate discovery is undertaken pursuant to "discovery on demand" type arrangements, or with respect to existing product candidates. Collaborations can be initiated prior to or at the proof of concept stage, or after additional preclinical activities have been undertaken by Compugen. In 2002, Compugen established an affiliate, Evogene Ltd. (<font style="DISPLAY: inline; TEXT-DECORATION: underline">www.evogene.com</font>) (<font style="DISPLAY: inline; TEXT-DECORATION: underline">TASE: EVGN.TA</font>), to utilize certain of the Company's <font style="FONT-STYLE: italic; DISPLAY: inline">in silico</font> predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cgen.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may", "expects", "anticipates", "believes", and "intends", and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identifie
d and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Company contact:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Marjie Hadad</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Global Media Liaison</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Email: marjie@cgen.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel: +972-54-536-5220</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">2</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen_bw.jpg
<TEXT>
begin 644 compugen_bw.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`U@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`;O7.WOV'K0!Q/Q+\>ZOX5U&"RTSX<>*O$YD0N\VE
M10^7%Z`M(ZY/TH`\;^(`@\:>(7UG7_@=\:FN&0($M-?DM8D4=ECANU0?ES0!
MB2^%O#B0,TGP-^.BHHRQ?Q==!0/<F^P!0!RGC>UM+;3H?^$'^!OQ%U.^ED"M
M'J/Q(GMT`[;=EZS,Q.,`"@#Z`_9S^#^A^'K6P\;ZUX.&F>,I;8QNMSKEWJQL
M48Y,<<MPS%6(QNV@#.1DB@#V*@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`/"OCC\3M+U3[?X//A_XOVB6ESL?5/"NG21&;8>0DP&=A/=<
M9QUQ0!Y>+GPX/^6W[57T^U7G^-`#EG\.$<2_M4_^!=Y_C0!Y_P#$B]UC5/[0
M\/\`_"J/VBO$WAZX'EG^T_%<\*W2?[<)C;C/8DT`;7[%?P9\":G\9[76;SX`
M^,O!TOAH+J-I>:]K+7$#SJV$`C,2Y93\X.>"H-`'W30`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$=U&TMM)&DK0LZE5D3&5)'49XXH`^4
M?&]W'X2\4W?AW6OVEOC+'?6+!9%M_"K7$?(##;)'9,K#!'()H`R/^$KT?_HY
MOXV_^$;/_P#(%`%;6=>\.ZEHUYIE[^TK\;IK:\A>&:(>#[A"Z,,$!A8@KD$C
M((H`^=SH7@@$JNC_`+3CA3C<@AP?<90'\P*`/3?V5/'?AGX1_$<ZM;>%?C[=
MVNIQK97?]NV4=Q;P1EU/G%8T\SY.3A>2">"<"@#]!].NH+VP@O;60207$:R1
MNO1E(R#0!-0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&;
MXNL=4U'P]=66BZT^C7TJ8AOT@28PMV.QQM;Z&@#YN^(WQ%O/`/BN?PSXP_:M
MATG5;94:2VG\'1YVL,J00A!!'<$]".H-`&%_POC0_P#H\>Q_\(Y/_C=`',>/
M_'G@_P`97%I+J'[;6HV+V@94_LC1'L@P."=^Q1NZ<9Z<T`>.M\5?#Z2.B_&W
M]HR3:Q&^+3[5D;'=3]JY![&@#TS]E3]HKPQX5^)EIIM[XZ^,7B*SUZ>.R:#Q
M+HUMY,,KL%23S5N&=`"><`Y!Z<4`??M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`'@7QI^*MO\`\)6MKX+_`&A?A-X;CLD,%[9:S)%<
M3B<,<\B==N!QM(SG-`'(?\+1\6?]'7_`K_P'C_\`DF@!5^*'BLG!_:O^!6.X
M^SQ]/_`F@#PKXG?'K5;SQK>,G[7[:=]G(MS%X?\`"TALV*\%T)<[@?[P.#0!
MH?`KQUXP^('Q8T/POH/[6_B76KFZN5DDLE\,O$)(D.^3<Y;"#:",GUH`_1"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R=5\4^&=+OFLM2\
M1Z39W*`%H+B\CC=0>A*D@\T`>=_$CQQXODUI8_`7BOX5Q::JX9];U-VED;'.
M%CX`_$Y]J`.`9?&VXDS?LWY/)SO_`,*`.2^(WQ*7P&\,?B?7/V=+>6?E(;:S
MN+E\>I6-3@>YH`\Z\;_'2TUB&WCT'XK?!;PPT1)DEL_"D]PTOH#YT+``>PS[
MT`:7PB3XR_%&\FM/`'QL^'NK_9P3)/'X&1((SZ&1K4+N]LYH`^P?@=X'U+P=
MX3AB\2:Q9:[X@D&;O4K?2K>Q4YYV(D*+\@/3=DGK[``[B@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@#SGXC>,/B1IOB)[/P;X)\,ZSIZ(-UWJ/
MB;[$^_\`B41B"3@>I(^E`'DNI>$M4U'49]0U+]E[X,WMY=2&2:YN?$D<DDC'
MJ69K$DGW)H`KS>"6BA>67]E3X'QQQJ6=V\0P@*!U)/V#I0!X?\2]?T/4KR!?
M!.E?LJ^$H(AB9+BXM=2DF;_>DME"K[!<^_:@#'\-6/C/7M>M=%T#6?V6]1U.
M_D\JWM+/1K!Y97ZX`$'I0!],?L__`+-^K(PU/XR:-\,+D@,JZ)H?A"QCC]`T
MEQY>\]<[5"]!DGD4`?1/AO1=(\/:/#I6A:79:98VXQ':V4"PQ)]%4`"@"_0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?)4GPE>25Y)/V/-&
M9W8LS-XTC)8DY)/R^M`"?\*B_P"K.M$_\+./_P")H`JZW\([H:-=&Q_9`\,P
M7(B;RY;[Q>CP(<<,Z@`E1W&10!X[#X"\9R,L<?P7_9G>1B%"KJH)8]@!]KZF
M@#["_96^#6C?#_P[!KVI^!_!VA^,KV$I>OX;MG2&%"<B)&=W8XXW,",D>@%`
M'G/[57[;G@KX4^([KPEX:T:7Q;XALSLN!#.L5I:OG&QI`&+..ZJOMD&@#RC1
M_P#@H7XRT'Q:FG_$KX0+86QVR216DLL%U#$PR'"3##\<@94'U%`'U3\7_P!H
M/X<?#CX/Z;\1M:U-Y]-URWCN-*MK10UQ?[T#J$4D=B,DD`=S0!\GZ]_P4<\1
MR7KWF@?"*V31X9!&TM[?R.S$\X+)&%0D=N?QH`^B_P!D7]J;P;\<],U1(M.N
MO#NM:';_`&N]TZZD$J>3T,L<@`W*#@'(4@D<<YH`\'T__@HX9O%L6FS?"ZW@
MT][L0-?+K#R%8]^"X1;?+''(4=>E`&?XO_X*.ZM:^/98M#^&5JWA^VG,;)J%
MV\=[,@/7@;8F(_A(;'K0!I?&/_@HHECJEO:_#?P$+RU,4<TE[KDCQ;]P!*I$
MO.!R-Y;!P>,=0#V*X_:NT]?V)E^/4'A=GN!*EF=&FN?+#W!E$;A9=IRH!9@=
MO(&.*`/(/#G_``4>MKJPU634OA+=0W-K;^99V]GJ?G"9\\^8YB7RD`Y+8;Z4
M`=1^R-^W"_Q4^+MGX!\4>"[719]7+BQO;.],B;PI81NK*.2`?F!Z]J`*'Q[_
M`&^C\/OC)XB\$:9\,XM9@T&\-F+YM7,)F=0`_P`@A;&'W`<G.!0!U'[4/[8E
M_P#!N/P;;7/PZAU'4_$NC)JUU:G5#"++<<",'RF+\AADA>G2@#I?A=^U/I.J
M_LLWGQQ\>:"OA;2XKN2TM+*&Z^U2WK+PHCRB99FW`#H`I)(`.`#PG2?^"C>J
M7/C))KCX3^5X6A_X^S;7C37D*$X$@;8J<#^$@9/&X4`=-\%?V]-5^(WQE\/>
M`]/^$L5N-=U&.T^UG62QBB+9>39Y`R50,VW(Z8S0!WG[6W[9_@SX->*)/!^D
MZ'<>*_$MOL-S:P7"PP6N[^"27#'S,$':%/7DB@#R70_^"AOB#2/%<-C\1?A`
M^EV4Q21OL]S(ES#"V<2".5`)./=<X-`'LO[8G[6%A\%M#\&:GHGAJ+Q5#XSM
MI+VW;[<;4+`JQLK_`.K8G<)1C('0T`>/3_\`!1H-\/)]2A^&.S76O/LT-H;]
MWMHH]@;S)9?*7EB2%C4$G8Y)7Y=P!ZW^P+^U'>_'R\US0]>\,V^D:OHT:70D
ML9&:":%FV]&Y5@?<@@]L4`?2M`'SA\9O`?AK3/'=U+'\)?BEXG;4F:]EOM`U
ML+;B1V)9`KW494@]@N,$8]@#E/\`A&?#W_1N_P`<_P#P=Q__`"=0`V;PKX:F
MB>&7]G/XXO'(I5D;6HB&!X((^W=*`//_`(6?!^X'[0VC02_LI6&@>&UU,2PZ
MKJFJ$7,,*G<CM"+AE9QA<@;AF@#[@^).I7>C?#K7M7LHS)=:?I]Q<PJHR2Z1
MLR\#W%`'X[_LD6%CXM_:O\#P^*-4MXH+W7(KR[N+YP$G=6,VQB>"9'4)[EP.
M]`'U9^T5\6?V2/&OQWOX/$OP]\3>,/$,,R:3'>:4ZM#=NIVHL1$P#?,2`<<F
M@#R#_@J:'T?XZ:#X#LX'L]`\)^'+2VTJR8Y\F,@@Y/.X_*%SD_=H`O>//$O@
MOPS_`,$M?"/@?3-1TR\\1^+-5>^OX+:=&F@,<[L6D7[RX58DY_#(H`SOV&X=
M5\)?!KXS_%=T^SZ7;>&GT.WFD0[9[J9U.U#T.T`9]-ZT`<Y_P3:\+V?B;]KK
MPPFI1K)9Z(DVK2JPR,PQDH3_`,#*T`</XH^T_$W]IF]CA5/.\5>)##&%''[R
M?:/T-`'I/_!3?4]-D_:=G\.:,MNEAX0TNUTB-((@@4JFY@<>A;%`'7?M5'_A
M!O\`@GQ\&_AW'*L<^ONVOWD1^\05+(?I^^_2@#(_8L\2?#[P-^S7\9O$NOZS
MIR>(]2TPZ-IVF2RKY\JRQ.H*1GYF&]QDC@!><4`<U_P39T";5?VK_#^IXD6T
M\+PSZO=R!>$2.)@`3T&2P%`'G&EZG:>+/CY!K?BF_2RL]:\0"[U"[ER4B1Y]
M[D^P!_`4`>A?\%%?B#H_Q#_:AU?4_#6JP:IH6D6=OI6GW=N<QND:;GVG^)?-
M>3##@CD9%`'1?MLV&H>#O@!\"_AZ5EM[2'0IM8GC^8+)=3LI8GL2H)QW`<^M
M`$_P,\>?#7P%^P!\1M/DU.RF\=^-IVTQ=."DW'D[556/&`BJTK@YQGCK@4`5
M?^"7&BSW/[15]XG@LQ<R>$=`O=0@4C(\\IY:#TYW-0!Y7\"M%U_XG?M#:+8Q
M>)X=,U[6]0>\&M7RAUCN`KS>8PZ$EEX]R*`/5?C5X'T/Q9\6)-.^('[5VBZ_
MXJM672@5T*_NOFW';"LD,11L,Y'!."2.H(H`H_\`!1R7^Q_BUX8^&BWYNT^&
M_A+3=#DDVE0TJPAV8#W5HS^G:@#J/CY:Z;X&_P""9_PI\,1VD=OJOC34I-=N
M"8_GE1%<[R>N0LT`'L:`/6/^")7AB2/0/'OC211Y=U=6VEP-GH8D:20?^1HO
MRH`^[:`.<^)W@RQ\;^'/['O=6UW2D$BRBYT349;*<$=O,C(.#GD'B@#SW_AG
M#P__`-%)^+/_`(6%Y_\`%4`'_#.'A_\`Z*3\6?\`PL+S_P"*H`CTG]F'P!:?
M$'0_&MYKOC;6=8\.2^=83ZQK\]WY)ZD#>3\I[CO0![/)&KAE<!E88*D<8H`^
M4?BA^P!\(?$WB&YU71=2UGPW]KF,SVEFRO`I)RP16'RCT&<#M0!V/[/G['GP
M?^$_BF#Q/I]E>ZSK5FV^UN]5E#BV;D;D0`*&YZD$CJ,&@#H/VG/V;OAQ\<;>
MWF\4VMS;:O91^5;:K92;)HTR3L(/#+DYP1QV(H`\9\'_`/!.OX5Z;J8N-<\4
M>(M7A4@_9PR0!L=B5&<?3%`'N_Q'^`_@3Q5\!H_A!;6TV@>&(3&8[?2F",H1
MMV,MDG)Y).2222<F@#D/@)^R1\._A)JNMZEX:U+6I+O6],DTMY;J5&:&-R"Q
M0A1AN!S0!@?"O]AOX3^`_B)HGC'3=3\07-YH5TEY!%<SH8S(ARI("CH<'\*`
M(_B3^PQ\+O&_CW6/%VLZ_P")C?ZU=/=3A+A`H9CT'R].U`'RE_P5HUNS;]H7
M2?!NGLJV7@_1(+.-`1\A;YL?4*%H`]/_`&=_V)?`_P`3_P!F+P9XJU?4=3T+
M7M1@DNI[FS(83Q/(3'N5N`0F,$8X-`'U?^SA\!?A]\%?"EUHOA33Y)9-1Q]N
MOKUO,FNL`@!CT"@$_*!CF@#Q]O\`@G[\&&\>MKC7VO?V8TIE_L43J(AEL[=^
M-VSMC.<=Z`)O$7[`_P`&]6\576MM>ZY:_:KDW!L[:6-((P6R$5=O"@<?2@#@
M/^"F'Q(\`:-XDTOX7_$7X27VL:?IUHEWH^KVNH_99%#*$<(=IX!4!E.0=JG'
M`H`^5OBOXF^`"?!BVT?X8^"M;M/$VIW,<VI:AKDPF-I$F3Y4##&=S;23M!PI
M'>@#[3_X)*?!W5_`?PVUCQIXITJXT[4_%<B);VMTFR1+5`2K,IY&YF)P>P%`
M%GXH_P#!/WX2>)O$MQJV@ZIJWAB.ZD,C6%GLDMXR>HC5A\HSVS@=L"@#L/V?
MOV-?A!\*?%=KXHLX-0UK6;')M[C4Y0Z0L?XUC``##L3G%`&9\7_V)/AG\1OB
M/K7C77]?\2C4M;G,\WE3H$3@*JJ-O0*%`SZ4`='\>?V5O`?Q7TSPKIFN:KK=
MI8^#[`V%A;64JJH4A`6.5/S$1H/PH`[;]FWX1>&O@I\.CX.\+37<UFUU)>/+
M=L&D=WP#D@`<!0/PH`[^@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^1_VD_\`
MDM6N?2'_`-%B@#Z5^$'_`"2SP]_V#X?_`$`4`='0`4`%`'S?_P`%.?\`DWZ+
J_K_7_P!!-`'P?_P3B_Y._P##7_;;_P!!-`'[`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
